• Home
  •  / Capricor Therapeutics

Capricor Therapeutics

OverviewSuggest Edit

Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. Its lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry − cardiovascular disease.
TypePublic
Founded2005
HQBeverly Hills, CA, USMap
Websitecapricor.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)18(-53%)
Revenue (FY, 2020)$310.3 K(-69%)
Share Price (Dec 2021)$2.9(-2%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Capricor Therapeutics

Karen Krasney

Karen Krasney

Executive Vice President and General Counsel
AJ Bergmann

AJ Bergmann

CFO
Show more

Capricor Therapeutics Office Locations

Capricor Therapeutics has an office in Beverly Hills
Beverly Hills, CA, US (HQ)
8840 Wilshire Blvd
Show all (1)

Capricor Therapeutics Financials and Metrics

Capricor Therapeutics Revenue

Capricor Therapeutics's revenue was reported to be $310.25 k in FY, 2020
USD

Revenue (Q1, 2021)

40.8k

Net income (Q1, 2021)

(5.2m)

EBIT (Q1, 2021)

(5.2m)

Market capitalization (31-Dec-2021)

72.4m

Closing stock price (31-Dec-2021)

2.9

Cash (31-Mar-2021)

41.9m

EV

30.9m
Capricor Therapeutics's current market capitalization is $72.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.4m195.5k503.2k4.8m5.5m4.0m2.7m1.7m1.0m310.3k

Revenue growth, %

851%15%(28%)

General and administrative expense

2.1m1.6m2.2m3.0m4.4m4.9m4.8m4.9m3.6m5.5m

R&D expense

4.1m1.0m5.2m7.8m13.8m16.0m10.8m12.1m5.1m8.5m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

346.0k813.0k195.5k1.0m1.0m1.3m1.8m1.3m1.3m1.2m1.1m746.8k880.8k996.5k313.3k400.1k404.0k219.2k230.5k410.4k142.1k185.7k49.9k40.8k

General and administrative expense

523.3k499.3k500.0k442.0k397.2k262.5k384.6k852.3k665.7k819.7k1.4m926.3k972.8k1.1m1.4m1.3m1.2m1.2m1.1m1.4m1.2m1.3m976.5k831.9k912.0k1.1m1.6m1.9m

R&D expense

702.9k1.5m465.4k332.5k179.1k62.6k36.5k1.4m1.9m2.0m3.8m3.4m3.2m4.3m4.3m4.7m3.3m3.1m1.9m2.7m3.4m3.1m1.8m1.6m1.2m1.9m3.3m

Operating expense total

1.2m2.0m965.4k774.4k576.3k325.1k421.1k2.2m2.5m2.8m5.2m4.4m4.2m5.4m5.7m6.0m4.4m4.4m3.0m4.1m4.6m4.4m2.8m2.5m912.0k2.3m3.5m5.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.0m46.7k1.7m8.0m5.6m3.2m6.1m4.3m3.9m32.7m

Accounts Receivable

Prepaid Expenses

271.3k124.9k222.8k235.5k210.6k501.2k724.2k571.4k1.0m

Inventories

342.9k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

3.3m2.6m435.7k777.2k282.5k285.0k229.2k71.0k13.0m11.6m9.8m6.9m5.0m4.2m11.8m8.9m18.0m2.8m8.3m8.9m7.2m6.3m4.4m7.2m5.9m6.8m13.2m36.3m41.9m

Prepaid Expenses

379.9k420.7k220.4k164.7k155.8k112.7k60.1k38.0k169.6k123.1k105.1k203.0k130.7k92.5k321.4k239.3k118.2k398.2k239.3k190.3k522.3k388.1k426.4k425.9k375.4k129.2k434.0k249.9k736.4k

Current Assets

3.6m3.0m656.1k941.8k438.3k404.3k289.3k109.0k14.0m16.4m14.2m25.4m21.6m17.7m14.9m11.8m22.4m13.5m13.6m15.2m14.6m13.5m11.4m7.9m6.6m7.3m13.8m36.6m42.6m

PP&E

12.7k10.9k8.0k6.4k4.9k1.2k994.0828.0163.5k204.0k224.5k253.8k263.1k332.1k345.0k355.3k351.5k411.9k399.0k394.0k535.2k507.4k622.3k541.7k506.7k474.7k410.9k486.8k838.7k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(4.9m)(1.9m)(8.9m)(6.2m)(12.9m)(18.8m)2.4m(15.2m)(7.6m)(13.7m)

Depreciation and Amortization

7.5k6.3k26.9k41.9k110.9k125.7k144.2k157.7k172.0k143.9k

Accounts Payable

105.5k(254.9k)974.7k70.3k831.2k508.3k(1.5m)(347.4k)(273.2k)1.8m

Cash From Operating Activities

(4.6m)(2.2m)(6.1m)958.6k(10.8m)(15.8m)(14.2m)(13.9m)(6.8m)(10.1m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(2.1m)(3.2m)(771.9k)(1.1m)(1.7m)(482.8k)(1.1m)(1.4m)(1.2m)(2.7m)(4.3m)(3.5m)(6.6m)(9.5m)(4.3m)(9.0m)(14.3m)(3.7m)(7.1m)(9.9m)(3.7m)(7.8m)(11.9m)(2.5m)(4.6m)(6.2m)(2.1m)(5.6m)(5.2m)

Depreciation and Amortization

4.1k5.9k1.8k3.4k4.8k1.0k1.2k1.4k6.5k16.2k28.4k24.8k51.0k79.8k31.6k65.1k91.8k38.8k76.1k109.6k34.1k73.0k114.4k43.3k86.4k129.2k33.0k65.6k50.1k

Accounts Payable

(94.6k)172.0k(110.7k)(316.1k)(227.8k)66.4k214.7k156.3k12.1k176.8k106.6k1.0m979.6k609.4k693.5k393.1k1.4m(533.0k)(861.0k)(1.8m)(87.9k)(289.9k)247.5k314.0k371.7k(201.2k)420.6k879.6k744.6k

Cash From Operating Activities

(2.4m)(3.1m)(603.5k)(1.5m)(2.0m)(144.2k)(200.0k)(358.2k)11.3m5.3m3.1m(2.1m)(3.9m)(7.2m)(4.2m)(9.1m)(11.6m)(4.7m)(8.4m)(11.6m)(3.4m)(7.1m)(10.1m)(1.6m)(3.4m)(5.0m)(1.2m)(3.2m)(3.3m)
show all
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Capricor Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

Learn more about our premium products
CSRHub logo

Capricor Therapeutics Online and Social Media Presence

Capricor Therapeutics's Trends

Embed Graph

Capricor Therapeutics Company Culture

  • CEO Rating

    F

    10/100

Learn more on Comparably

Capricor Therapeutics News and Updates

December 13, 2021

Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19

Capricor’s Exosome-based mRNA Vaccine for SARS-CoV-2-In-Vivo Preclinical Data Published in the Journal of Biological Chemistry--Preclinical Data Demonstrates Strong T-Cell Response for High Conserved N Protein which may Confer Longer Lasting Immunity--Completing Non-Clinical Studies for IND Submissi…
September 24, 2021

Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002

–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–
September 22, 2021

Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences

- Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 -
September 07, 2021

Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

-Conference Dates: September 13–15, 2021- -Conference Dates: September 13–15, 2021-
September 02, 2021

Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021

-Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS- -Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS-
August 05, 2021

Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12

Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET
Show more

 Capricor Therapeutics Frequently Asked Questions

  • When was Capricor Therapeutics founded?

    Capricor Therapeutics was founded in 2005.

  • Who are Capricor Therapeutics key executives?

    Capricor Therapeutics's key executives are Karen Krasney and AJ Bergmann.

  • How many employees does Capricor Therapeutics have?

    Capricor Therapeutics has 18 employees.

  • What is Capricor Therapeutics revenue?

    Latest Capricor Therapeutics annual revenue is $310.3 k.

  • What is Capricor Therapeutics revenue per employee?

    Latest Capricor Therapeutics revenue per employee is $17.2 k.

  • Who are Capricor Therapeutics competitors?

    Competitors of Capricor Therapeutics include Keros Therapeutics, 19Labs and Winnoz Technology.

  • Where is Capricor Therapeutics headquarters?

    Capricor Therapeutics headquarters is located at 8840 Wilshire Blvd, Beverly Hills.

  • Where are Capricor Therapeutics offices?

    Capricor Therapeutics has an office in Beverly Hills.

  • How many offices does Capricor Therapeutics have?

    Capricor Therapeutics has 1 office.